These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29048416)

  • 1. Increased Frequency of KRAS Mutations in African Americans Compared with Caucasians in Sporadic Colorectal Cancer.
    Staudacher JJ; Yazici C; Bul V; Zeidan J; Khalid A; Xia Y; Krett N; Jung B
    Clin Transl Gastroenterol; 2017 Oct; 8(10):e124. PubMed ID: 29048416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
    Du L; Kim JJ; Shen J; Chen B; Dai N
    Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of key driver genes in colorectal cancer progression and metastasis.
    Huang D; Sun W; Zhou Y; Li P; Chen F; Chen H; Xia D; Xu E; Lai M; Wu Y; Zhang H
    Cancer Metastasis Rev; 2018 Mar; 37(1):173-187. PubMed ID: 29322354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of MSI frequency and race in colorectal cancer.
    Ashktorab H; Ahuja S; Kannan L; Llor X; Ellis NA; Xicola RM; Laiyemo AO; Carethers JM; Brim H; Nouraie M
    Oncotarget; 2016 Apr; 7(23):34546-57. PubMed ID: 27120810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
    Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
    Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
    Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
    Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
    Oliveira C; Velho S; Moutinho C; Ferreira A; Preto A; Domingo E; Capelinha AF; Duval A; Hamelin R; Machado JC; Schwartz S; Carneiro F; Seruca R
    Oncogene; 2007 Jan; 26(1):158-63. PubMed ID: 16953233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients.
    Liu Y; Meucci S; Sheng L; Keilholz U
    Oncotarget; 2017 Sep; 8(44):77928-77941. PubMed ID: 29100436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Genetic Factors to Inform Reducing Colorectal Cancer Disparitites in African Americans.
    Carethers JM
    Front Oncol; 2018; 8():531. PubMed ID: 30524961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer.
    Sahnane N; Magnoli F; Bernasconi B; Tibiletti MG; Romualdi C; Pedroni M; Ponz de Leon M; Magnani G; Reggiani-Bonetti L; Bertario L; Signoroni S; Capella C; Sessa F; Furlan D;
    Clin Epigenetics; 2015; 7():131. PubMed ID: 26697123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC.
    Gilsing AM; Fransen F; de Kok TM; Goldbohm AR; Schouten LJ; de Bruïne AP; van Engeland M; van den Brandt PA; de Goeij AF; Weijenberg MP
    Carcinogenesis; 2013 Dec; 34(12):2757-66. PubMed ID: 23983135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of genetic ancestry as a risk factor for incidence of non-small cell lung cancer in the US.
    James BA; Williams JL; Nemesure B
    Front Genet; 2023; 14():1141058. PubMed ID: 37082203
    [No Abstract]   [Full Text] [Related]  

  • 19. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer.
    Tanaka H; Deng G; Matsuzaki K; Kakar S; Kim GE; Miura S; Sleisenger MH; Kim YS
    Int J Cancer; 2006 Jun; 118(11):2765-71. PubMed ID: 16381005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.